GlobeNewswire

Mercedes-AMG Petronas Motorsport and Rubrik Announce New Partnership

Dela
  • Pioneer in Cloud Data Management to work with Mercedes-AMG Petronas Motorsport team to accelerate the protection of race data
  • Team to use Rubrik's data backup and recovery technology at their headquarters to improve data management

PALO ALTO, Calif. and LONDON, Sept. 12, 2017 (GLOBE NEWSWIRE) -- Mercedes-AMG Petronas Motorsport and Rubrik, the Cloud Data Management company, today announced a new partnership.

With data volumes, backup and recovery requirements becoming ever more demanding in Formula One, the team is investing in class-leading technology in order to stay ahead. Specifically, the team will be using a multi-node Rubrik cluster at their Brackley headquarters to protect their critical race data.

Mercedes-AMG Petronas Motorsport will also use Rubrik's REST API (Application Programming Interface) to integrate with their current tools to analyze their data utilization. With this information, the team expects to become even more efficient in how it manages and utilizes the vast volumes of race data.

"We are delighted to welcome Rubrik to Mercedes-AMG Petronas Motorsport," commented Toto Wolff, head of Mercedes-Benz motorsport. "In the fast-moving world of information technology, it's essential to be right at the forefront, particularly for us in the area of data management, and we look forward to working with Rubrik to maximize our potential in this area."

"Mercedes-AMG Petronas Motorsport is at the forefront of adopting new technologies within the racing world," said Bipul Sinha, co-founder and CEO, Rubrik. "Rubrik's cloud data management platform will enable the team to access and manage critical race information, providing them with a new competitive edge. We are excited to partner with Mercedes-AMG Petronas Motorsport to turbocharge their innovative approach to data management and contribute to their continued success."

About Rubrik
Rubrik delivers instant application availability with data protection, search, analytics, archival and copy data management. Hybrid Cloud enterprises benefit from Rubrik's market-leading Cloud Data Management platform with simplicity, instant data access, app-mobility, policy-driven automation, Ransomware protection, and analytics at scale. Rubrik has been named to Gartner's Cool Vendors in Storage Technologies 2016 and recognized by Forbes on the Cloud 100 and as a Next Billion Dollar Startup.

For more information, visit www.rubrik.com and follow @rubrikInc on Twitter.

Mercedes-AMG Petronas Motorsport Digital Channels & Resources
Media Site:      media.mercedesamgf1.com
Website:          mercedesamgf1.com
App (iOS):       App Store
App (Android): Google Play

Facebook:       /MercedesAMGF1
Twitter:            @MercedesAMGF1
Instagram:       /MercedesAMGF1
YouTube:        /MercedesAMGF1
Google+:         +MercedesAMGF1

Contacts
Bradley Lord, Tel: +44 1280 844484, Email: blord@MercedesAMGF1.com
Nicola Armstrong, Tel: +44 1280 844096, Email: narmstrong@MercedesAMGF1.com

Emily Iwan, Tel: +1 844 478-2745, Email: emily.iwan@rubrik.com
Jon Bawden, Tel: +44 1291 637644, Email: jonb@wearecohesive.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Rubrik via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum